Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
Status:
Withdrawn
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 randomized study to assess the safety and efficacy of COVI-MSC in the
setting of current standard of care treatments for subjects hospitalized subjects with acute
respiratory distress syndrome not related to COVID-19 infection.